In a scientific first, Harvard Stem Cell Institute scientists have successfully grown the cells that line the blood vessels — called vascular endothelial cells — from human induced pluripotent stem cells (iPSCs), revealing new details about how these cells function. Using a unique approach, the researchers induced the differentiation of specific cell types by generating mechanical forces on the surface of the iPSC-derived endothelium mimicking the flow of blood. For example, cells that felt a stronger “flow” became artery cells, while those that felt a weaker “flow” became vein cells.
“It was especially exciting to us to discover that these cells are basically responding to biomechanical cues,” research leader Guillermo García-Cardena, PhD, an HSCI Affiliated Faculty member, said. “By exposing cells to ‘atheroprone flow,’ we can direct differentiation of these cells into cells that are present in areas of the circulatory system that we know are affected by diseases like atherosclerosis.” García-Cardena is now working on modeling the formation of arterial plaques using human iPSC-derived vascular endothelial cells and identifying potential drugs that might prevent plaque formation.
García-Cardena’s team, which included Harvard School of Engineering and Applied Sciences graduate student William Adams, found that the iPS-derived human endothelial cells display three critical functions carried out by mature endothelium in the body: mounting inflammatory responses, keeping blood from leaking out of the blood vessel, and preventing blood clots.
Based on this information, García-Cardena’s work, published this month in the journal Stem Cell Reports, has another exciting implication — it could potentially reduce, or even eliminate the need for heparin use during kidney dialysis and lung failure treatment — making both markedly safer.
Traditionally, patients undergoing dialysis are treated with heparin, a powerful drug, which prevents the blood from clotting as it’s routed through the dialysis machine. While heparin is quite effective in preventing clotting, because it considerably thins the blood, it can also cause loss of blood, internal bleeding, and interfere with the healing process.
“The iPSC-derived endothelial cells cells beautifully function as an anticoagulant surface,” said García-Cardena, an Associate Professor of Pathology at Harvard Medical School and Brigham and Women’s Hospital. “In the future, we may take a tissue sample from a patient, generate iPSCs, and then cover an extracorporeal device with the patient’s own endothelial cells — so the patient can go home with the device without the need for regular heparin shots.”
Share this story on Facebook, Twitter, and Google:
Other social bookmarking and sharing tools:
The above story is based on materials provided by Harvard University, via EurekAlert!, a service of AAAS. The original article was written by Joseph Caputo.
Note: Materials may be edited for content and length. For further information, please contact the source cited above.
William J. Adams, Yuzhi Zhang, Jennifer Cloutier, Pranati Kuchimanchi, Gail Newton, Seema Sehrawat, William C. Aird, Tanya N. Mayadas, Francis W. Luscinskas, Guillermo García-Cardeña. Functional Vascular Endothelium Derived from Human Induced Pluripotent Stem Cells. Stem Cell Reports, 2013; 1 (2): 105 DOI: 10.1016/j.stemcr.2013.06.007
Note: If no author is given, the source is cited instead.
Number of stories in archives: 141,490
Interested in ad-free access? If you’d like to read ScienceDaily without ads, let us know!
more breaking science news
Follow ScienceDaily on Facebook, Twitter, and Google:
Recommend ScienceDaily on Facebook, Twitter, and Google +1:
Other social bookmarking and sharing tools:
… from NewsDaily.com
more science news
In Other News …
more top news
Science Video News
Unraveling Brain Tumors
Brain tumor researchers have found that brain tumors arise from cancer stem cells living within tiny protective areas formed by blood vessels in the. … > full story
Strange Science News
… from ScienceDaily
Get the latest science news with our free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:
… we want to hear from you!
Tell us what you think of ScienceDaily — we welcome both positive and negative comments. Have any problems using the site? Questions?